AADI BIOSCIENCES DL-0001
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides a three-asset antibody-drug conjugate (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in March 2025. Whitehawk Therapeutics, Inc. was incorporated in 200… Read more
Market Cap & Net Worth: AADI BIOSCIENCES DL-0001 (3350)
AADI BIOSCIENCES DL-0001 (F:3350) has a market capitalization of $158.67 Million (€154.58 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #20105 globally and #2155 in its home market, demonstrating a -1.20% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AADI BIOSCIENCES DL-0001's stock price €3.28 by its total outstanding shares 47128362 (47.13 Million).
AADI BIOSCIENCES DL-0001 Market Cap History: 2019 to 2026
AADI BIOSCIENCES DL-0001's market capitalization history from 2019 to 2026. Data shows growth from $24.57 Million to $158.67 Million (21.09% CAGR).
AADI BIOSCIENCES DL-0001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AADI BIOSCIENCES DL-0001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 3350 by Market Capitalization
Companies near AADI BIOSCIENCES DL-0001 in the global market cap rankings as of March 18, 2026.
Key companies related to AADI BIOSCIENCES DL-0001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
AADI BIOSCIENCES DL-0001 Historical Marketcap From 2019 to 2026
Between 2019 and today, AADI BIOSCIENCES DL-0001's market cap moved from $24.57 Million to $ 158.67 Million, with a yearly change of 21.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €158.67 Million | +53.27% |
| 2025 | €103.52 Million | -28.19% |
| 2024 | €144.16 Million | +59.36% |
| 2023 | €90.46 Million | -83.86% |
| 2022 | €560.44 Million | -43.76% |
| 2021 | €996.54 Million | +2524.20% |
| 2020 | €37.98 Million | +54.53% |
| 2019 | €24.57 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of AADI BIOSCIENCES DL-0001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $158.67 Million USD |
| MoneyControl | $158.67 Million USD |
| MarketWatch | $158.67 Million USD |
| marketcap.company | $158.67 Million USD |
| Reuters | $158.67 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.